Drugs / GS-9911
last change Oct 2023 re-read 2 minutes ago

GS-9911

Developed for
cancer
Investigated by
Gilead Sciences

Trials 1 · a red edge is where a trial was stopped

2024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06082960 Oct 2023 → Dec 2026 expected cancer Gilead Sciences Active not recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as GS-9911 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06082960